| アブストラクト | PURPOSE: Small-molecule protein kinase inhibitors (PKIs) have substantially improved clinical outcomes of various diseases. However, some studies suggested these agents might induce acute kidney injury (AKI). This study was designed to comprehensively assess the adverse events of AKI in real-world patients receiving small-molecule PKIs using the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). METHODS: The FAERS data between 2004 and 2019 were extracted to describe the characteristics of AKI cases after the use of small-molecule PKIs approved by the FDA. The reporting odds ratio (ROR) with 95% confidence interval (CI) for AKI was calculated for each small-molecule PKI agent. A disproportionality signal was defined when the lower limit of 95% CI > 1. RESULTS: Among the 462,020 adverse event reports for small-molecule PKIs, 9970 (2.16%) were identified as AKI cases. The median AKI onset time was 32 (interquartile range 11-124) days after the initiation of small-molecule PKI treatment. A total of 61.38% and 26.04% of AKI cases resulted in hospitalization and death, respectively. Based on RORs, 14 of 52 small-molecule PKIs yielded disproportionality signals for AKI, including six VEGFR inhibitors, three mTOR inhibitors and five small-molecule PKIs with other targets. The agents with the highest AKI RORs were entrectinib (ROR 6.40, 95% CI 2.23, 18.34), sirolimus (ROR 3.76, 95% CI 3.45, 4.09), and cobimetinib (ROR 3.40, 95% CI 2.69, 4.28). CONCLUSION: Analysis of the FAERS data helped identify the small-molecule PKIs that were most frequently reported for AKI. Further investigations are needed to confirm these potential risks. |
|---|
| ジャーナル名 | Cancer chemotherapy and pharmacology |
|---|
| 投稿日 | 2020/10/2 |
|---|
| 投稿者 | Fan, Qianqian; Ma, Jie; Zhang, Bo; Li, Qiuyue; Liu, Fang; Zhao, Bin |
|---|
| 組織名 | Department of Pharmacy, Peking Union Medical College Hospital, No. 1 Shuaifuyuan,;Dongcheng District, Beijing, 100730, China.;Departemnt of Nephrology, Peking Union Medical College Hospital, No. 1;Shuaifuyuan, Dongcheng District, Beijing, 100730, China.;Dongcheng District, Beijing, 100730, China. zhaobin@pumch.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33001273/ |
|---|
